Stockscreener 앱 받기
1.32
3.94%
0.05
시간 외 거래:
1.34
0.02
+1.52%
전일 마감가:
$1.27
열려 있는:
$1.27
하루 거래량:
38,362
Relative Volume:
0.32
시가총액:
$55.88M
수익:
-
순이익/손실:
$-31.39M
주가수익비율:
-1.5714
EPS:
-0.84
순현금흐름:
$-18.45M
1주 성능:
-1.49%
1개월 성능:
-8.97%
6개월 성능:
+70.32%
1년 성능:
+25.71%
1일 변동 폭
$1.26
$1.35
1주일 범위
$1.26
$1.42
52주 변동 폭
$0.5116
$2.45
Quince Therapeutics Inc Stock (QNCX) Company Profile
명칭
Quince Therapeutics Inc
전화
415-910-5717
주소
611 GATEWAY BLVD., SUITE 273, SOUTH SAN FRANCISCO
QNCX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
QNCX
Quince Therapeutics Inc
|
1.32 | 55.88M | 0 | -31.39M | -18.45M | -0.84 |
|
VRTX
Vertex Pharmaceuticals Inc
|
483.49 | 124.48B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
625.60 | 67.45B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
583.62 | 35.60B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
266.83 | 34.53B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
274.78 | 29.15B | 3.81B | -644.79M | -669.77M | -6.24 |
Quince Therapeutics Inc Stock (QNCX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-03-24 | 개시 | Oppenheimer | Outperform |
Quince Therapeutics Inc 주식(QNCX)의 최신 뉴스
Quince Therapeutics (QNCX) Expected to Announce Earnings on Monday - Defense World
Oppenheimer Initiates Coverage on Quince Therapeutics (NASDAQ:QNCX) - MarketBeat
Analysts Are Bullish on Top Healthcare Stocks: Quince Therapeutics (QNCX), Lucid Diagnostics (LUCD) - The Globe and Mail
Quince Therapeutics (NASDAQ:QNCX) Price Target Lowered to $4.00 at D. Boral Capital - Defense World
Quince Therapeutics Reports 2024 Financial Results and Trial Progress - TipRanks
Quince Therapeutics stock target cut to $4 from $12, maintains buy By Investing.com - Investing.com South Africa
Quince Therapeutics stock target cut to $4 from $12, maintains buy - Investing.com
Quince Therapeutics (NASDAQ:QNCX) Now Covered by Oppenheimer - Defense World
Quince Therapeutics Existing Cash Position To Provide Operating Runway Through Phase 3 Topline Results Into 2026 - MarketScreener
Quince Therapeutics Provides Business Update and Reports Fiscal Year 2024 Financial Results - Business Wire
Oppenheimer sets $10 target for Quince Therapeutics stock By Investing.com - Investing.com South Africa
Oppenheimer Initiates Coverage of Quince Therapeutics (QNCX) with Outperform Recommendation - Nasdaq
Oppenheimer Initiates Quince Therapeutics at Outperform -March 24, 2025 at 07:46 am EDT - Marketscreener.com
Oppenheimer sets $10 target for Quince Therapeutics stock - Investing.com
Quince Advances Rare Disease Drug Trial with FDA Fast Track Status, $40M War Chest - Stock Titan
Quince Therapeutics (QNCX) Projected to Post Earnings on Monday - Defense World
Analysts Set Quince Therapeutics, Inc. (NASDAQ:QNCX) Target Price at $9.50 - Defense World
Quince Therapeutics (NASDAQ:QNCX) versus IN8bio (NASDAQ:INAB) Critical Contrast - Defense World
Market Momentum Report: Quince Therapeutics Inc (QNCX)’s Negative Close at 1.41 - The Dwinnex
Vaxart (NASDAQ:VXRT) vs. Quince Therapeutics (NASDAQ:QNCX) Critical Comparison - Armenian Reporter
Ataxia Treatment Market Size in the 7MM is expected to grow - openPR
Financial Survey: Quince Therapeutics (NASDAQ:QNCX) & Vaxart (NASDAQ:VXRT) - Defense World
Head to Head Comparison: Quince Therapeutics (NASDAQ:QNCX) and Quantum Genomics Société Anonyme (OTCMKTS:QNNTF) - Defense World
Spotlight On Fractyl Health And Two Other Intriguing Penny Stocks - Simply Wall St
Quince Therapeutics, Inc. (NASDAQ:QNCX) Receives $9.50 Average Price Target from Analysts - Defense World
Quince Therapeutics, Inc. (NASDAQ:QNCX) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat
D. Boral Capital Reiterates "Buy" Rating for Quince Therapeutics (NASDAQ:QNCX) - MarketBeat
Quince Therapeutics to Host Investor Webinar Today Focused on Addressing the High Unmet Need in Ataxia-Telangiectasia - Business Wire
Quince Therapeutics secures USPTO nod for A-T treatment patent - MSN
D. Boral Capital Reaffirms “Buy” Rating for Quince Therapeutics (NASDAQ:QNCX) - Defense World
Quince Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference - Marketscreener.com
Quince Therapeutics secures USPTO nod for A-T treatment patent By Investing.com - Investing.com Australia
Quince Therapeutics Receives Notice of Allowance Covering Innovative Method of Use for Lead Indication Ataxia-Telangiectasia - Business Wire
Ataxia Telangiectasia Market on Track for Major Expansion by 2032, According to DelveInsight | Acasti Pharma Inc., IntraBio Inc - The Globe and Mail
Earnings Coming in Better-Than-Expected As Peak Season Begins - The Globe and Mail
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
Meta Platforms Is Surging on Q4 Earnings. Is Meta Stock a Buy, Sell, or Hold for 2025? - The Globe and Mail
Quince Therapeutics, Inc. (NASDAQ:QNCX) Receives $9.50 Average PT from Brokerages - Defense World
Earnings To Watch: Kirby (KEX) Reports Q4 Results Tomorrow - The Globe and Mail
Quince Therapeutics to Host Investor Webinar on February 7, 2025 Focused on Addressing the High Unmet Need in Ataxia-Telangiectasia - Business Wire
Quince Therapeutics, Inc. Announces Frontiers in Neurology Publication of Long-Term Safety of EryDex in Pediatric Patients with Ataxia-Telangiectasia - Marketscreener.com
Quince Therapeutics Announces Frontiers in Neurology Publication of Long-Term Safety of EryDex in Pediatric Patients with Ataxia-Telangiectasia - Business Wire
Quince Therapeutics, Inc. (NASDAQ:QNCX) Receives $9.50 Consensus Target Price from Brokerages - MarketBeat
Quince Therapeutics Appoints Renowned Pediatric Neurologist Dr. William Whitehouse to Scientific Advisory Board - Business Wire
BioXcel Therapeutics expands board, appoints new director - Investing.com
Geode Capital Management LLC Purchases 66,170 Shares of Quince Therapeutics, Inc. (NASDAQ:QNCX) - Defense World
Quince Therapeutics, Inc. (NASDAQ:QNCX) Receives $8.67 Average Target Price from Analysts - Defense World
Pharma Innovator Unlocks Multi-Disease Treatment Potential - Streetwise Reports
Quince Therapeutics’ (QNCX) “Buy” Rating Reaffirmed at D. Boral Capital - Defense World
Quince Therapeutics, Inc. (NASDAQ:QNCX) Receives $8.67 Consensus Target Price from Brokerages - MarketBeat
Quince Therapeutics' (QNCX) "Buy" Rating Reiterated at D. Boral Capital - MarketBeat
Quince Therapeutics Inc (QNCX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.00%
자본화:
|
볼륨(24시간):